Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Stibogluconate in MDS/AML with p53 Mutations
NCT04906031Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Jinan University
- Start
- Jun 2020
- Primary completion
- Feb 2023
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of sodium stibogluconate in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Jinan University. Status: unknown.
02
Drugs
sodium stibogluconate
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04906031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906031.